Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vaccine therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    366 result(s) found for: Vaccine therapy. Displaying page 3 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-002348-57 Sponsor Protocol Number: 2021-002348-57 Start Date*: 2021-05-30
    Sponsor Name:Medical University of Vienna
    Full Title: A Randomized, Parallel Group, Single-Blind, Phase 2 Study to Evaluate the immune response of two classes of SARS-Cov-2 Vaccines employed as Third Vaccination in Patients under current Rituximab The...
    Medical condition: Vaccination against SARS-CoV-2 in patients with rituximab therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005059-18 Sponsor Protocol Number: 116886 Start Date*: 2013-05-24
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: A Phase III, randomised, observer-blind, placebo-controlled, multicentre clinical study to assess the immunogenicity and safety of GSK Biologicals? HZ/su candidate vaccine when administered intramu...
    Medical condition: Herpes Zoster (HZ) and its related complications
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) BE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000849-50 Sponsor Protocol Number: MI-CP114 Start Date*: 2017-12-12
    Sponsor Name:MedImmune
    Full Title: A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of...
    Medical condition: The prevention of Influenza Virus in Immunocompromised children ages 5 through 17 years of age.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-000302-10 Sponsor Protocol Number: UHKT-COVID19 Start Date*: 2022-01-24
    Sponsor Name:Institute of hematology and blood transfusion
    Full Title: Significance of T cell response to vaccination against SARS-CoV2 for leukemic patients with weakend immune system
    Medical condition: Recipients of cell therapy (allo HSCT, CAR19 T cells) indicated to vaccination against COVID19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011617-25 Sponsor Protocol Number: V503-002 Start Date*: 2009-10-16
    Sponsor Name:MSD Finland Oy
    Full Title: A Study to Demonstrate Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents an...
    Medical condition: Cervical Cancer
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000260-99 Sponsor Protocol Number: 10102010 Start Date*: 2011-04-12
    Sponsor Name:Department of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8
    Full Title: Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled Trial
    Medical condition: The primary objectives of this study are to: 1. Prospectively evaluate immunological response to vaccination with the 23-valent polysaccharide vaccine (PPV23) in HIV infected patients over a one y...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016789-10 Sponsor Protocol Number: 02-04-80 Start Date*: 2010-02-19
    Sponsor Name:Div KIR AMC
    Full Title: Efficacy of the H1N1 Flu (swine flu) vaccination in patients with Rheumatoid Arthritis treated with rituximab
    Medical condition: To assess the efficacy of A/H1N1 vaccination in patients treated with rituximab therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001453-74 Sponsor Protocol Number: Version01.1. Start Date*: 2012-05-15
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Comparison of vaccination routes: subcutaneus versus intramuscular application of FSME-Immun®
    Medical condition: TBE vaccine (FSME-Immun®) is registered for intra-muscular application. Due to medical reasons (e.g. anticoagulant therapy, adipositas) intra-muscular application is not always possible. The aim o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004933-14 Sponsor Protocol Number: V502-003-01 Start Date*: 2006-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 45, 52, and 58.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011564-11 Sponsor Protocol Number: B1851021(6115A1-3002-WW) Start Date*: 2012-01-31
    Sponsor Name:Wyeth Pharmaceuticals Inc. (a Pfizer Company)
    Full Title: A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 2 and 3 Doses of 13-valent Pneumococcal Conjugate Vaccine in Human Immunodeficiency Virus-Infecte...
    Medical condition: Pneumococcal infection in HIV infected subjects
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001452-55 Sponsor Protocol Number: 204852 Start Date*: 2018-11-26
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biolog...
    Medical condition: Chronic hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002978-36 Sponsor Protocol Number: OVG2014/08 Start Date*: 2015-01-26
    Sponsor Name:The University of Oxford
    Full Title: Vaccines Against Salmonella Typhi: a phase IIb, single centre, observer-blind, randomised controlled trial to assess the immunogenicity and protective efficacy of Vi conjugated (Vi-TCV) and unconju...
    Medical condition: Salmonella enterica serovar Typhi infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10039446 Salmonella typhi infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-003458-22 Sponsor Protocol Number: BNT162-17 Start Date*: 2021-10-04
    Sponsor Name:BioNTech SE
    Full Title: A Phase II trial to evaluate the safety and immunogenicity of SARS-CoV-2 monovalent and multivalent RNA-based vaccines in healthy subjects
    Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2).
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    23.1 10021881 - Infections and infestations 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017295-24 Sponsor Protocol Number: 997262001 Start Date*: 2010-03-10
    Sponsor Name:University Hospital Motol
    Full Title: Phase I/II clinical trial:Immunotherapy of hormone-refractory prostate cancer patients with dendritic cell-based vaccine (Fáze I/II klinické studie imunoterapie hormonálně refrakterního karcinomu p...
    Medical condition: Patients with hormone-refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017259-91 Sponsor Protocol Number: 997262002 Start Date*: 2010-03-10
    Sponsor Name:University Hospital Motol
    Full Title: Phase I/II clinical trial: Immunotherapy of prostate cancer patients in biochemical relapse with dendritic cell-based vaccine
    Medical condition: Patients with prostate cancer in the stage of biochemical relapse
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003563-36 Sponsor Protocol Number: ACQUIVAS Start Date*: 2018-07-30
    Sponsor Name:Cambridge University Hospital NHS Foundation Trust and University of Cambridge
    Full Title: ACQUIVAS - Acquired immunodeficiency in ANCA associated vasculitis (AAV)
    Medical condition: Pneumococcal vaccine responses in ANCA associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-004058-28 Sponsor Protocol Number: HN017/HBV-003 Start Date*: 2006-02-02
    Sponsor Name:Henogen
    Full Title: A phase III multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, to th...
    Medical condition: Female and male pre-dialysis, peritoneal dialysis and haemodialysis patients with documented evidence of nonresponse to previous hepatitis B vaccination [non-response to previous hepatitis B vaccin...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018097-64 Sponsor Protocol Number: 114083 Start Date*: 2010-03-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Long-term follow-up of study participants from GlaxoSmithKline (GSK) Biologicals’-sponsored clinical trials evaluating Human Immunodeficiency Virus vaccine [F4co (p24-RT-Nef-p17)/AS01B vaccine] (73...
    Medical condition: ART-treated and ART-naïve HIV-infected adults (ART: anti-retroviral therapy)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018770-20 Sponsor Protocol Number: DC-005 Start Date*: 2010-05-21
    Sponsor Name:Oslo University Hospital
    Full Title: Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.
    Medical condition: Prostatic cancer patients who have received curative surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002546-20 Sponsor Protocol Number: 104820 Start Date*: 2006-11-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV 16/18 L1/AS04 vaccine administered intramuscularly ac...
    Medical condition: For active immunization of girls and women from 10 years of age onwards for the prevention of persistent human papillomavirus (HPV) infections and related clinical outcomes (cytological abnormaliti...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 08:47:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA